Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2555
Abstract: Consensus is lacking regarding the optimal salvage therapy for patients with follicular lymphoma who relapse after or are refractory to immunochemotherapy. read more here.
Keywords: adapted treatment; response adapted; treatment rituximab; rituximab bendamustine ... See more keywords
COASTAL: A PHASE 3 STUDY OF THE PI3Kδ INHIBITOR ZANDELISIB WITH RITUXIMAB (R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN’S LYMPHOMA (INHL)
Sign Up to like & getrecommendations! Published in 2021 at "Hematological Oncology"
DOI: 10.1002/hon.174_2880
Abstract: TPS7573Background: Patients (pts) with iNHL treated with front-line immunochemotherapy may benefit from an alternative, chemotherapy-free regimen at relapse. Zandelisib, a potent, selective, and st... read more here.
Keywords: immunochemotherapy; study pi3k; coastal phase; inhibitor zandelisib ... See more keywords
Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2378
Abstract: Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive… read more here.
Keywords: lymphoma; predictive factors; immunochemotherapy; follicular lymphoma ... See more keywords
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Haematology"
DOI: 10.1111/bjh.17513
Abstract: Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clinical challenge. Front‐line ‘attenuated’ or low‐intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report outcomes of attenuated immunochemotherapy in 95 patients… read more here.
Keywords: immunochemotherapy; analysis; mantle cell; dose ... See more keywords
Predictive model of postoperative pneumonia after neoadjuvant immunochemotherapy for esophageal cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of gastrointestinal oncology"
DOI: 10.21037/jgo-22-149
Abstract: Background Postoperative pneumonia (PP) is the most common pulmonary complication of esophagectomy. It is of great importance to identify any high-risk factors and prevent pulmonary complications to improve the prognosis of patients with esophageal cancer… read more here.
Keywords: esophageal cancer; postoperative pneumonia; immunochemotherapy; neoadjuvant immunochemotherapy ... See more keywords
Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers
Sign Up to like & getrecommendations! Published in 2022 at "Translational Lung Cancer Research"
DOI: 10.21037/tlcr-22-439
Abstract: Background This retrospective study aimed to evaluate the real-world efficacy of neoadjuvant immunochemotherapy in locally advanced stage III non-small cell lung cancer (NSCLC), with a particular focus on analyzing the optimal treatment cycle and peripheral… read more here.
Keywords: locally advanced; lung cancer; immunochemotherapy locally; neoadjuvant immunochemotherapy ... See more keywords
Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Current Oncology"
DOI: 10.3390/curroncol28020126
Abstract: Background: Our study measured the body composition of Diffuse large B-cell lymphoma (DLBCL) patients receiving rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimen by computed tomographic (CT) and assessed their correlation with treatment-related toxicity… read more here.
Keywords: immunochemotherapy; body composition; toxicity; diffuse large ... See more keywords